NMTR · 9 Meters Biopharma, Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 | Q2 '21 | Q1 '21 | Q4 '20 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - |
| R&D | $9.80M | - | $6.30M | $7.55M | $8.37M | - | $6.05M | $5.71M | $2.60M | - |
| SG&A | $2.99M | - | $2.42M | $3.65M | $3.00M | - | $2.39M | $2.55M | $2.21M | - |
| Total Operating Expenses | $12.79M | - | $8.72M | $11.20M | $11.36M | - | $13.54M | $8.26M | $5.40M | - |
| D&A | $1.3K | - | - | - | $1.6K | - | - | - | $1.1K | - |
| Operating Income | ($12.79M) | - | ($8.72M) | ($11.20M) | ($11.36M) | - | ($13.54M) | ($8.26M) | ($5.40M) | - |
| Interest Expense | $752.8K | - | $847.3K | $0 | $304 | - | $2.0K | $1.2K | $44.1K | - |
| Income Tax | $0 | - | $0 | $0 | $0 | - | $0 | $0 | $0 | - |
| Net Income | ($13.87M) | - | ($9.35M) | ($11.13M) | ($11.35M) | - | ($13.54M) | ($8.25M) | ($5.43M) | - |
| EPS - Basic | ($1.02) | - | ($0.72) | ($0.04) | ($0.04) | - | ($0.06) | ($0.03) | ($0.09) | - |
| EPS - Diluted | ($1.02) | - | ($0.72) | ($0.04) | ($0.04) | - | ($0.05) | ($0.03) | ($0.09) | - |
Balance Sheet
| Line item | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 | Q2 '21 | Q1 '21 | Q4 '20 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $6.94M | $12.65M | $15.86M | $29.46M | $37.24M | $46.99M | $53.61M | $64.02M | $37.85M | $37.85M |
| Accounts Receivable | - | - | - | - | - | - | - | - | - | - |
| Inventory | - | - | - | - | - | - | - | - | - | - |
| Accounts Payable | $4.23M | $5.05M | $1.44M | $2.33M | $1.91M | $2.43M | $1.32M | $1.64M | $1.37M | $1.49M |
| Current Assets | $9.20M | $33.02M | $18.45M | $31.35M | $39.09M | $49.99M | $56.48M | $65.78M | $39.98M | $38.93M |
| Total Assets | $9.31M | $33.15M | $42.14M | $31.51M | $39.26M | $50.17M | $56.68M | $65.99M | $40.21M | $39.16M |
| Current Liabilities | $15.58M | $30.70M | $12.86M | $9.34M | $8.22M | $8.46M | $7.28M | $6.72M | $5.99M | $6.85M |
| Long-term Debt | - | - | $15.74M | - | - | - | - | - | - | - |
| Total Liabilities | $15.61M | $30.75M | $28.67M | $9.42M | $8.32M | $8.57M | $7.41M | $6.86M | $6.14M | $7.02M |
| Stockholders' Equity | ($6.30M) | $2.40M | $13.46M | $22.09M | $30.94M | $41.60M | $49.27M | $59.14M | $34.07M | $32.14M |
| Retained Earnings | ($226.48M) | ($212.61M) | ($200.68M) | ($191.32M) | ($180.19M) | ($168.84M) | ($159.29M) | ($145.75M) | ($137.49M) | ($132.06M) |
Cash Flow
| Line item | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 | Q2 '21 | Q1 '21 | Q4 '20 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | ($9.75M) | - | - | - | ($9.75M) | - | - | - | ($6.22M) | - |
| Investing Cash Flow | $0 | - | - | - | ($2.8K) | - | - | - | ($5.0K) | - |
| Financing Cash Flow | ($12.29M) | - | - | - | $0 | - | - | - | $6.87M | - |
| CapEx | $0 | - | - | - | $2.8K | - | - | - | $0 | - |
| Free Cash Flow | ($9.75M) | - | - | - | ($9.75M) | - | - | - | ($6.22M) | - |
Ratios
| Metric | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 | Q2 '21 | Q1 '21 | Q4 '20 |
|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||
| Gross margin | - | - | - | - | - | - | - | - | - | - |
| Operating margin | - | - | - | - | - | - | - | - | - | - |
| EBITDA margin | - | - | - | - | - | - | - | - | - | - |
| Net margin | - | - | - | - | - | - | - | - | - | - |
| Free cash flow margin | - | - | - | - | - | - | - | - | - | - |
| FCF / Net income | 0.70 | - | - | - | 0.86 | - | - | - | 1.15 | - |
| R&D / Revenue | - | - | - | - | - | - | - | - | - | - |
| SG&A / Revenue | - | - | - | - | - | - | - | - | - | - |
| Effective tax rate | - | - | - | - | - | - | - | - | - | - |
| Return on assets | -148.9% | - | -22.2% | -35.3% | -28.9% | - | -23.9% | -12.5% | -13.5% | - |
| Return on equity | 220.2% | - | -69.5% | -50.4% | -36.7% | - | -27.5% | -14.0% | -15.9% | - |
| Return on invested capital | - | - | -23.6% | - | - | - | - | - | - | - |
| Liquidity | ||||||||||
| Current ratio | 0.59 | 1.08 | 1.43 | 3.36 | 4.75 | 5.91 | 7.76 | 9.80 | 6.68 | 5.68 |
| Quick ratio | 0.59 | 1.08 | 1.43 | 3.36 | 4.75 | 5.91 | 7.76 | 9.80 | 6.68 | 5.68 |
| Cash ratio | 0.45 | 0.41 | 1.23 | 3.15 | 4.53 | 5.56 | 7.36 | 9.53 | 6.32 | 5.53 |
| Leverage | ||||||||||
| Debt / Equity | - | - | 1.17 | - | - | - | - | - | - | - |
| Debt / Assets | - | - | 0.37 | - | - | - | - | - | - | - |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Interest coverage | -17.0x | - | -10.3x | - | -37382.4x | - | -6872.9x | -7156.4x | -122.5x | - |
| Equity multiplier | -1.48 | 13.81 | 3.13 | 1.43 | 1.27 | 1.21 | 1.15 | 1.12 | 1.18 | 1.22 |
| Liabilities / Assets | 1.68 | 0.93 | 0.68 | 0.30 | 0.21 | 0.17 | 0.13 | 0.10 | 0.15 | 0.18 |
| Efficiency | ||||||||||
| Asset turnover | - | - | - | - | - | - | - | - | - | - |
| Inventory turnover | - | - | - | - | - | - | - | - | - | - |
| Days sales outstanding | - | - | - | - | - | - | - | - | - | - |
| Days inventory outstanding | - | - | - | - | - | - | - | - | - | - |
| Days payable outstanding | - | - | - | - | - | - | - | - | - | - |
| Cash conversion cycle | - | - | - | - | - | - | - | - | - | - |
| Valuation | ||||||||||
| P / E | - | - | - | - | - | - | - | - | - | - |
| P / B | - | - | - | - | - | - | - | - | - | - |
| P / S | - | - | - | - | - | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Growth | ||||||||||
| Revenue growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| Revenue CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| Revenue CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Gross profit growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| Operating income growth (YoY) | -12.5% | - | 35.6% | -35.6% | -110.5% | - | -114.8% | 81.6% | - | - |
| Net income growth (YoY) | -22.2% | - | 30.9% | -34.9% | -109.0% | - | -62.5% | 81.5% | -50.7% | - |
| EPS growth (YoY) | -2450.0% | - | -1340.0% | -33.3% | 55.6% | - | - | - | - | - |
| EPS CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| FCF growth (YoY) | 0.0% | - | - | - | -56.6% | - | - | - | - | - |
| FCF CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Book value growth (YoY) | - | -94.2% | -72.7% | -62.7% | -9.2% | 29.4% | 1260.9% | 1828.0% | - | - |
Peer comparison
Same SIC group: Pharmaceutical Preparations
Comparing 9 METERS BIOPHARMA against the 5 most active filers in the same SIC group.